Protalix BioTherapeutics FY 2025 R&D expenses rose 51% to USD 19.57 million as net loss totaled USD 6.6 million

Reuters

Mar 18

Protalix BioTherapeutics FY 2025 R&D expenses rose 51% to USD 19.57 million as net loss totaled USD 6.6 million

Protalix published a press release with full-year fiscal 2025 financial and business results. Revenues from selling goods were USD 51.8 million, down 2%, driven mainly by lower sales to Chiesi due to a change in average net selling price and inventory quantities. R&D expenses were USD 19.6 million, up 51%, primarily due to preparations for the RELEASE Phase 2 study of PRX-115. Net loss was USD 6.6 million, and cash, cash equivalents and short-term bank deposits were USD 30.3 million. The company said the European Commission approved a 2mg/kg every-4-weeks dosing regimen for Elfabrio in adults with Fabry disease, triggering entitlement to a USD 25 million milestone payment from Chiesi, and it forecast 2026 total revenue of USD 78 million to USD 83 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603180650PR_NEWS_USPR_____LN11956) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620232200"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620232200\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620232200?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620232200","market":"fut","top_or_hot":-1,"title":"Protalix BioTherapeutics FY 2025 R&D expenses rose 51% to USD 19.57 million as net loss totaled USD 6.6 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protalix BioTherapeutics FY 2025 R&amp;D expenses rose 51% to USD 19.57 million as net loss totaled USD 6.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Protalix published a press release with full-year fiscal 2025 financial and business results. Revenues from selling goods were USD 51.8 million, down 2%, driven mainly by lower sales to Chiesi due to a change in average net selling price and inventory quantities. R&amp;D expenses were USD 19.6 million, up 51%, primarily due to preparations for the RELEASE Phase 2 study of PRX-115. Net loss was USD 6.6 million, and cash, cash equivalents and short-term bank deposits were USD 30.3 million. The company said the European Commission approved a 2mg/kg every-4-weeks dosing regimen for Elfabrio in adults with Fabry disease, triggering entitlement to a USD 25 million milestone payment from Chiesi, and it forecast 2026 total revenue of USD 78 million to USD 83 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PLX\">Protalix BioTherapeutics Inc</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603180650PR_NEWS_USPR_____LN11956) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protalix BioTherapeutics FY 2025 R&D expenses rose 51% to USD 19.57 million as net loss totaled USD 6.6 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtalix BioTherapeutics FY 2025 R&D expenses rose 51% to USD 19.57 million as net loss totaled USD 6.6 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protalix BioTherapeutics FY 2025 R&amp;D expenses rose 51% to USD 19.57 million as net loss totaled USD 6.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Protalix published a press release with full-year fiscal 2025 financial and business results. Revenues from selling goods were USD 51.8 million, down 2%, driven mainly by lower sales to Chiesi due to a change in average net selling price and inventory quantities. R&amp;D expenses were USD 19.6 million, up 51%, primarily due to preparations for the RELEASE Phase 2 study of PRX-115. Net loss was USD 6.6 million, and cash, cash equivalents and short-term bank deposits were USD 30.3 million. The company said the European Commission approved a 2mg/kg every-4-weeks dosing regimen for Elfabrio in adults with Fabry disease, triggering entitlement to a USD 25 million milestone payment from Chiesi, and it forecast 2026 total revenue of USD 78 million to USD 83 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PLX\">Protalix BioTherapeutics Inc</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603180650PR_NEWS_USPR_____LN11956) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7wgwjZ:1","article_id":"2620232200","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620232200","pubTimestamp":1773831033,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Protalix published a press release with full-year fiscal 2025 financial and business results. Revenues from selling goods were USD 51.8 million, down 2%, driven mainly by lower sales to Chiesi due to a change in average net selling price and inventory quantities. R&D expenses were USD 19.6 million, up 51%, primarily due to preparations for the RELEASE Phase 2 study of PRX-115. Net loss was USD 6.6 million, and cash, cash equivalents and short-term bank deposits were USD 30.3 million. The company said the European Commission approved a 2mg/kg every-4-weeks dosing regimen for Elfabrio in adults with Fabry disease, triggering entitlement to a USD 25 million milestone payment from Chiesi, and it forecast 2026 total revenue of USD 78 million to USD 83 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PLX":"Protalix BioTherapeutics Inc"},"translate_title":"Protalix Biotherapeutics 2025财年研发费用增长51%至1,957万美元，净亏损总计660万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLX":0.9},"content_text":"Protalix BioTherapeutics FY 2025 R&D expenses rose 51% to USD 19.57 million as net loss totaled USD 6.6 million\n    \n\n        Protalix published a press release with full-year fiscal 2025 financial and business results. Revenues from selling goods were USD 51.8 million, down 2%, driven mainly by lower sales to Chiesi due to a change in average net selling price and inventory quantities. R&D expenses were USD 19.6 million, up 51%, primarily due to preparations for the RELEASE Phase 2 study of PRX-115. Net loss was USD 6.6 million, and cash, cash equivalents and short-term bank deposits were USD 30.3 million. The company said the European Commission approved a 2mg/kg every-4-weeks dosing regimen for Elfabrio in adults with Fabry disease, triggering entitlement to a USD 25 million milestone payment from Chiesi, and it forecast 2026 total revenue of USD 78 million to USD 83 million.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603180650PR_NEWS_USPR_____LN11956) on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}